# CORRESP — Rani Therapeutics Holdings, Inc.  (RANI)  (CIK 0001856725)

> <strong>Rani Therapeutics Holdings, Inc.  (RANI)  (CIK 0001856725) → SEC staff</strong> · filed 2025-12-01 · ticker RANI · SIC 2834

## What is this

A CORRESP letter is the company's written reply to the SEC during a filing review. Responses include accounting position arguments, restatement assessments, and clarifying disclosures. Released to EDGAR alongside the SEC's UPLOAD letters.

## Key facts

- **Accession number:** 0001193125-25-303863
- **Form:** CORRESP
- **Filer:** Rani Therapeutics Holdings, Inc.  (RANI)  (CIK 0001856725)
- **CIK:** 0001856725
- **Ticker:** RANI
- **Filed:** 2025-12-01
- **SIC industry:** 2834
- **HQ:** San Jose, CA

## Primary source

PDF letter: https://www.sec.gov/Archives/edgar/data/1856725/000119312525303863/filename1.htm

EDGAR review history for this filer: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1856725&type=UPLOAD&dateb=&owner=include&count=40

## Citation

> US Securities and Exchange Commission, EDGAR CORRESP comment letter, Rani Therapeutics Holdings, Inc.  (RANI)  (CIK 0001856725) (CIK 0001856725), filed 2025-12-01, accession 0001193125-25-303863. Retrieved via MORVS 2026-11-17 from https://api.morvs.ai/comment-letter/0001193125-25-303863.

---

*[SEC comment letters dataset](/datasets/sec-comment-letters) · CC0 1.0*
